Q3 2024 Earnings Call Transcript October 30, 2024 AbbVie Inc. beats earnings expectations. Reported EPS is $3, expectations ...

AbbVie’s Rinvoq, meanwhile ... a follow-up to its 2015 infusion pump Duopa. With a non-surgical, continuous delivery system, the drug has the potential to “significantly expand use” beyond ...

AbbVie bumped earnings guidance higher following strong third-quarter sales as gains from the company's newer anti-inflammatory drugs offset expected declines from its former top dog, Humira. The ...

(Reuters) -AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings, ...

This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Good morning. It’s a very ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

a Represents net earnings attributable to AbbVie Inc. Acquisition and integration costs primarily reflect integration costs related to the Allergan acquisition, including a one-time gain of $169 ...

LATEST NEWS 05:00 How to pick the life insurance policy that’s right for you 05:00 Dublin AI start-up Glitch set to launch online ad platform 05:00 Movers & Shakers: MSD Ireland, Edelman, Ergo, Fáilte ...

NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...

AbbVie Inc. discovers, develops ... Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for ...